GeneDx Holdings

WGS · NASDAQ

$68.74+$2.45 (+3.70%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $66.29

WGS analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 9 analysts

Average $94.22 (+37.1% upside)

Low: $74.74
Now: $68.74
High: $108.15

Upgrades and downgrades

The latest rating actions, newest first

WGS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Guggenheim	Oct 1, 2026	Maintains	Buy	$74.00 → $83.00	66%
Canaccord Genuity	Aug 4, 2026	Maintains	Buy	$75.00 → $90.00	55%
BTIG	Aug 4, 2026	Maintains	Buy	$90.00	54%
Guggenheim	Jun 29, 2026	Maintains	Buy	$70.00 → $74.00	66%
Piper Sandler	Jun 23, 2026	Maintains	Overweight	$50.00 → $63.00	58%
Canaccord Genuity	May 5, 2026	Maintains	Buy	$100.00 → $75.00	55%
Wells Fargo	May 5, 2026	Maintains	Overweight	$155.00 → $75.00	66%
Guggenheim	May 5, 2026	Maintains	Buy	$100.00 → $70.00	66%
BTIG	May 5, 2026	Maintains	Buy	$170.00 → $90.00	54%
Canaccord Genuity	Apr 20, 2026	Maintains	Buy	$170.00 → $100.00	55%

The case for and against

Updated Oct 15, 2026

Bull case

GeneDx Holdings is supported by a favorable reimbursement and adoption backdrop, as Carelon’s outpatient genome coverage policy moves whole genome sequencing toward a first-line, medically necessary option when criteria are met, reducing reimbursement uncertainty and encouraging an exome-to-genome mix shift. That shift already lifted WGS volumes to 47% of Q4’25 volumes from 43% in Q3’25 and should support higher ASPs and gross margins, with the policy potentially adding about $100 in incremental ASP by H2 2027. The company also has multiple growth levers from 2026 execution, including 30%+ volume growth in WES/WGS, a near tripling of the sales force to ~160 reps, new product launches, and the Fabric Genomics acquisition, which can broaden commercialization and improve long-term profitability.

Bear case

GeneDx Holdings is facing a weakened fundamental backdrop as Q1'26 revenue of $102M missed expectations, adjusted gross margin of 68.5% trailed consensus, and adjusted net income was negative $8M, despite WES/WGS volumes rising 34% Y/Y to 27,488. Its outlook also deteriorated when it cut 2026 revenue guidance by $65M to $475M-$490M and reduced core exome/genome growth expectations, suggesting the business is still highly exposed to reimbursement, mix pressure, and uneven non-core demand. The fact that the miss came from five separate buckets, alongside concerns about guidance reliability and a projected 2028 adjusted net income of only $25M versus a prior $82.5M estimate, supports a cautious view.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.